Keywords: Genmab, Janssen, Johnson & Johnson, Daratumab, HuMax-CD38, Multiple myeloma, License deal, Equity stake

Genmab leaps on $1.1 billion daratumumab deal with Janssen

Article | 31 August 2012

Print This

Denmark’s Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday, after ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in